IP Library Granted Patent US 11,510,987
Granted Patent B2
US 11,510,987 · App. 16/426,184 · Granted Nov 29, 2022

Endocytosis enhancer for drug delivery system

Inventors: Miho Suzuki (Saitama, JP); Ken Hatano (Saitama, JP); Shojiro Yoshida (Saitama, JP); Yasuhiro Yamashita (Tokyo, JP)
Assignees: Saitama University; QUARRYMEN & Co. Inc.
A61K47/42A61K9/107A61K38/1732A61K38/22A61K39/395A61K47/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,510,987
App. No.
16/426,184
Granted
Nov 29, 2022
Kind
B2
Abstract

The present invention addresses the problem of providing an endocytosis enhancer comprising associates formed from a fluorescent protein. The fluorescent protein is preferably any one selected from the group consisting of a white fluorescent protein, a red fluorescent protein, a yellow fluorescent protein, a blue fluorescent protein and a green fluorescent protein. The endocytosis enhancer according to the present invention can enhance the cellular uptake of a drug, which is encapsulated in micelles each formed from a fluorescent-protein-supported carbosilane dendrimer, through endocytosis.

Claims (13)

1. An endocytosis enhancing preparation comprising more than one fusion polypeptide comprising a fluorescent protein, and a target recognition sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3.

2. The endocytosis enhancing preparation according to claim 1 , wherein said fluorescent proteins are selected from the group consisting of white fluorescent protein, red fluorescent protein, yellow fluorescent protein, blue fluorescent protein, and green fluorescent protein.

3. The endocytosis enhancing preparation according to claim 2 comprising, 2 to 10 molecules of the fluorescent protein.

4. The endocytosis enhancing preparation according to claim 2 further comprising a backbone structure shown in the following formula (I) where n is an integer from 1 to 6 and wherein a micelle is formed

5. The endocytosis enhancing preparation according to claim 2 , wherein the fluorescent protein is green fluorescent protein (GFP) and further comprising a backbone structure selected from the group consisting of the compound shown in the following formula (III) to (VI):

6. The endocytosis enhancing preparation according to claim 1 , comprising 4 to 10 molecules of the fluorescent protein.

7. The endocytosis enhancing preparation according to claim 1 further comprising a backbone structure shown in the following formula (I) where n means an integer from 1 to 6 and wherein a micelle is formed

8. The endocytosis enhancing preparation according to claim), wherein said backbone structure shown in the formula (I) is a compound shown in the following formula (II)

9. The endocytosis enhancing preparation according to claim 1 , wherein said micelle is formed so as to have the protein on the outside in the aqueous medium, having a diameter from 50 to 500 nm, and emitting fluorescence derived from FRET.

10. The endocytosis enhancing preparation according to claim 7 , wherein said micelle is formed so as to have the protein on the outside in the aqueous medium, having a diameter from 50 to 500 nm, and emitting fluorescence derived from FRET.

11. The endocytosis enhancing preparation according to claim 10 , said micelle include any one selected from the group consisting of the molecule having not larger than the molecular weight of 200,000, a nucleic acid, and a lipophilic molecule.

12. The endocytosis enhancing preparation according to claim 11 , said molecule having not larger than the molecular weight of 200,000 is preferably selected from the group consisting of immunoglobulin G, lectin, and peptide hormone.

13. The endocytosis enhancing preparation according to claim 1 , wherein the fluorescent protein is green fluorescent protein (GFP) and further comprising a backbone structure selected from the group consisting of the compound shown in the following formula (III) to (VI):

Assignments (2)
CHANGE OF NAME Recorded Jun 8, 2023
From: QUARRYMEN&CO. INC.
To: CYSAY INC.
Reel/Frame 063928/0184 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2021
From: SUZUKI, MIHO; HATANO, KEN; YAMASHITA, YASUHIRO
To: SAITAMA UNIVERSITY; QUARRYMEN&CO. INC.
Reel/Frame 057928/0479 →
Priority Claims (1)
JP 2016-234547 · Dec 1, 2016 · national
Continuity (2)
Continuation PCTJP2017043373 · Dec 1, 2017
Related Publication 20190358333A1 · Nov 28, 2019